<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="81216">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02048059</url>
  </required_header>
  <id_info>
    <org_study_id>ANG1005-CLN-04</org_study_id>
    <nct_id>NCT02048059</nct_id>
  </id_info>
  <brief_title>ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases</brief_title>
  <official_title>A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Angiochem Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Angiochem Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2 study to see if an investigational drug, ANG1005, can shrink tumor cells
      in breast cancer patients with recurrent brain metastases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      See above.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intracranial objective response rate</measure>
    <time_frame>Upon enrollment through end of study period (1 year after last patient is enrolled)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of intracranial objective response</measure>
    <time_frame>Upon enrollment through end of study period (1 year after last patient is enrolled)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median intracranial progression free survival (PFS)</measure>
    <time_frame>Upon enrollment through end of study period (1 year after last patient is enrolled)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intracranial PFS rates at 3, 6 and 12 months</measure>
    <time_frame>Upon enrollment through end of study period (1 year after last patient is enrolled)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-month overall survival rate</measure>
    <time_frame>Upon enrollment through end of study period (1 year after last patient is enrolled</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extracranial ORR</measure>
    <time_frame>Upon enrollment through end of study period (1 year after last patient is enrolled</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients with adverse events</measure>
    <time_frame>Upon enrollment through end of study period (1 year after last patient is enrolled</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>On Day 1 of Cycles 1 and 3</time_frame>
    <description>To determine the drug concentration and distribution in the plasma. (AUC, Cmax, T1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Upon enrollment through end of study period (1 year after last patient is enrolled)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intracranial clinical benefit at 3 and 6 months</measure>
    <time_frame>Upon enrollment through end of study period (1 year after last patient is enrolled)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Brain Metastases</condition>
  <arm_group>
    <arm_group_label>ANG1005</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ANG1005</intervention_name>
    <arm_group_label>ANG1005</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ≥ 18 years old

          2. Breast cancer

          3. Recurrent brain metastases from breast cancer

          4. At least one radiologically-confirmed and measurable metastatic brain lesion ( ≥ 0.5
             cm)

          5. Neurologically stable

          6. Karnofsky Performance Status (KPS) score ≥ 70

        Exclusion Criteria:

          1. Prior treatment with ANG1005/GRN1005

          2. Pregnancy or lactation

          3. Inadequate bone marrow reserve

          4. Any evidence of severe or uncontrolled diseases

          5. Patients with the presence of an infection including abscess or fistulae, or known
             infection with hepatitis B or C or HIV

          6. CNS disease requiring immediate neurosurgery intervention (e.g., resection, shunt
             placement, etc.)

          7. Known allergy to paclitaxel or any of its components
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Betty Lawrence</last_name>
    <role>Study Director</role>
    <affiliation>Angiochem Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0698</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California - LAC Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California - Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC - Irvine Chao Family Comprehensive Cancer Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GRU Cancer Center - Georgia Regents University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland - Greenebaum Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer &amp; Hematology Centers of Western Michigan</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico</name>
      <address>
        <city>Alburquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Long Islan Brain Tumor Center at Neurological Surgery P.C.</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7295</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Magee Womens Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univeristy of Texas Health Science Center in San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/22203732</url>
    <description>Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors</description>
  </link>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 11, 2017</lastchanged_date>
  <firstreceived_date>January 21, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ANG1005</keyword>
  <keyword>GRN1005</keyword>
  <keyword>LRP-1</keyword>
  <keyword>Targeted therapy</keyword>
  <keyword>Breast cancer</keyword>
  <keyword>Brain metastases</keyword>
  <keyword>Brain tumor</keyword>
  <keyword>Blood-brain barrier</keyword>
  <keyword>Trastuzumab</keyword>
  <keyword>Herceptin</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Taxol</keyword>
  <keyword>Breast cancer with brain metastases</keyword>
  <keyword>Triple Negative</keyword>
  <keyword>TNBC</keyword>
  <keyword>HER2-positive</keyword>
  <keyword>HER2-negative</keyword>
  <keyword>Metastatic brain tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
